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Abstract
Metastatic disease is the principle cause of death from colorectal cancer. In that context, the most
significant indicator of overall survival and therapeutic response to adjuvant chemotherapy is the
presence of metastatic tumor cells in regional lymph nodes. Although histopathologic analysis of
lymph nodes is central to all colorectal cancer staging paradigms, its prognostic and predictive
value is limited. Indeed, about 30% of patients with histopathology-negative lymph nodes (pN0) die
from metastatic disease, reflected by microscopic lymph node metastases that are overlooked by
standard techniques. These unrecognized tumor cells are especially important when considering
racial disparities in outcomes in colorectal cancer patients, where blacks with lymph node-negative
disease have the largest discrepancies in outcomes, with more than 40% excess mortality compared to Caucasian patients. However, the significance of tumor cells in regional lymph nodes
remains uncertain, and approximately 50% of colorectal cancer patients with nodal metastases
detected by histopathology remain free of recurrent disease. Accurate identification of occult
metastases in regional lymph nodes, and defining their value as prognostic markers of recurrence
risk and predictive markers of response to adjuvant chemotherapy remains one challenge in the
management of colorectal cancer patients. Guanylyl cyclase C (GUCY2C), a receptor which is
expressed primarily in intestinal cells normally, but is universally over-expressed by colorectal
cancer cells, has been validated to detect prognostically significant occult metastases using quantitative RT-PCR (RT-qPCR). Biomarker validation was achieved through a prospective, multicenter, blinded clinical trial. In that trial, occult tumor burden estimated across all regional lymph
nodes by GUCY2C RT-qPCR predicted clinical outcomes, identifying node-negative patients with
a low (near zero) risk, and those with >80% risk, of developing disease recurrence. Moreover,
there was disproportionately higher occult tumor burden in black, compared to white, patients
which contributes to racial disparities in outcomes in colorectal cancer. The diagnostic paradigm
quantifying occult tumor burden using GUCY2C qRT-PCR is positioned to reduce racial disparities in colorectal cancer mortality.
Key words: Colorectal cancer; Early detection; Molecular stage; Cancer biomarkers; Guanylyl
cyclase C

Introduction
Metastases continue to be the principle cause of
mortality from colorectal cancer. In colorectal cancer
staging patients, the most significant prognostic indicator of survival and predictive indicator of re-

sponse to adjuvant therapy are metastatic cancer cells
in regional lymph nodes [1-3]. While histopathologic
assessment of lymph nodes is a core element of colorectal cancer staging algorithms, the prognostic and
http://www.jcancer.org
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predictive value of lymph node metastases is restricted [1-5]. Thus, about 30% of patients with histopathology-negative regional lymph nodes (stage I and
II) develop recurrent disease, likely reflecting the
presence of undetected metastases in those lymph
nodes [1-3]. Moreover, these undetected metastases
take on particular significance when considering racial disparities in colorectal cancer outcomes: African
Americans with node-negative colorectal cancer are
disadvantaged, with more than 40% excess mortality
compared to Caucasian patients with the same disease
[6-9]. However, the absolute significance of metastatic
tumor cells in lymph nodes remains unclear, and approximately 50% of patients with lymph node metastases identified by histopathology (stage III) remain
free of disease recurrence [1-3]. This discussion highlights the central importance of understanding how to
identify regional lymph node metastases and evaluate
their prognostic and predictive significance in managing black and white patients with colorectal cancer
[1-5, 10].
Guanylyl cyclase C (GUCY2C) is a receptor
which is typically restricted to intestinal epithelial
cells normally, but is universally over-expressed by
colorectal cancer cells. Because of this unique expression pattern, GUCY2C was validated to detect prognostically significant occult colorectal metastases by
quantitative RT-PCR (RT-qPCR). Validation was
achieved through a prospective, multicenter, blinded
clinical trial [11]. This biomarker platform has been
employed to generate a molecular staging algorithm
that quantifies occult metastatic cancer burden across
the regional lymph node network. In turn, this approach identifies histopathology node-negative colorectal cancer patients with near-zero risk, and those
with >80% risk, of developing disease recurrence
[12-14]. Moreover, there is disproportionate occult
tumor burden in African American, compared to
Caucasian, colorectal cancer patients which contributes to racial disparities in outcomes in this disease
[12].

Colorectal Cancer
Colorectal cancer continues to be the fourth most
common cause of cancer, with about 140,000 new
cases annually, and the second leading cause of cancer
mortality, resulting in approximately 10% of cancer-related deaths, or ~50,000 patients annually, in the
U.S. [1, 3, 15]. The significant impact of this disease
can best be appreciated by considering the communities at risk, which in the U.S. include >100 million
people >50 years. In colorectal cancer, mortality reflects metastatic disease, and about 20% of patients
have unresectable disease at presentation while more
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than 30% develop metastases after diagnosis. Surgery
continues to be the mainstay of management [1-3].
Yet, while “curative” surgery removes obvious tumor,
occult metastatic disease produces recurrences [1-3].
Indeed, recurrence rates range from about 10% for
disease limited to the epithelium (stage I) to more
than 60% for cancer that has metastasized to more
than 4 regional lymph nodes (stage III) [1-3].

Staging
The most significant prognostic marker of risk of
disease recurrence in colorectal cancer is metastatic
tumor cells in regional lymph nodes [1-3]. However,
current approaches to detecting metastases in regional
nodes remain inaccurate and their clinical significance
is not certain. While histopathology is the standard
approach, imprecision in staging by standard light
microscopy signifies significant methodological limitations [1-5, 11]. Thus, this approach is insensitive,
with the limit for detection of ~1 cancer cell in 200
normal cells in lymph nodes [16]. Further, typically
only one or a few sections from each lymph node are
examined, leaving more than 99.99% of each specimen
not reviewed, producing sampling error. Such limitations are evident when post-resection disease recurrence frequency is considered. Stage I and II disease,
limited to the intestinal wall without obvious evidence of spread beyond the bowel, should be curable
by surgery. Yet, rates of recurrence can be as high as
15% in stage I and 30% in stage II disease [1-3, 17].
Conversely, while all stage III patients have metastases in regional lymph nodes, only about 50% develop
recurrent metastatic disease. Thus, about 50% of colorectal patients with nodal metastases visible by microscopy remain disease-free. In that context, molecular markers that certify the clinical significance of
metastases in regional lymph nodes have yet to be
identified. Indeed, identifying regional lymph node
metastases and their clinical importance represents an
important gap in managing colorectal cancer patients
[10].
Beyond predicting disease recurrence, metastases in regional lymph nodes identify patients who
benefit from adjuvant chemotherapy. Adjuvant
chemotherapy incorporating 5-fluorouracil (5-FU)
and irinotecan or oxaliplatin, increases 5 year survival
from ~40% (untreated) to ~50% (treated) in patients
with stage III colon cancer [2, 18]. Limited therapeutic
benefit in some, but not all, patients with stage III
disease probably reflects stage heterogeneity, in
which some patients have clinically aggressive metastases. One limitation to managing these patients is
the inability to recognize clinically significant regional
lymph node metastases, resulting in toxic therapies
http://www.jcancer.org
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being administered to patients who derive no benefit,
and may suffer adverse reactions. This scenario is
even more complex for patients with stage I and II
disease who are lymph node-negative by histopathology. Indeed, here, the utility of therapy is uncertain, with small survival benefits revealed for stage
II patients in only some clinical trials [18, 19]. This
discussion highlights the unmet need for approaches
that detect occult tumor cells and define their prognostic and predictive value, to identify colorectal
cancer patients who derive the greatest benefit from
therapy [10].

Molecular approaches to staging offer advantages that
overcome limitations in histopathology, with the
ability to sample the entire specimen, overcoming
limitations in tissue sampling, and detect one tumor
cell in ~107 normal cells, overcoming limitations in
sensitivity [4, 5]. Early experience with RT-PCR has
been heterogeneous, because of inadequate sample
size, clinical follow-up, and techniques. However,
meta-analyses reveal the prognostic utility of occult
metastases in histopathology-negative regional lymph
nodes detected by RT-PCR in colorectal cancer patients [4, 5].

Racial disparities

GUCY2C is a molecular marker in colorectal cancer

While mortality from colorectal cancer decreases, there is an increasing racial gap in incidence and
outcomes [9, 20, 21]. There is about a 20% greater incidence of, and approximately a 40% greater death
rate from, colorectal cancer in African American,
compared to Caucasian, patients [7, 9, 20, 21]. These
disparities reflect advanced stage at diagnosis, socioeconomic factors, and differences in disease management [6-9, 22-24]. However, beyond these parameters which influence overall disease outcomes, there
are racial differences in stage-specific outcomes [6, 8,
9, 25]. Unexpectedly, the biggest differences in outcomes occur in disease at the earliest stages, with
more than 40% excess mortality in African Americans
with lymph node-negative colorectal cancer, compared to Caucasians. These stage-specific differences
do not reflect socioeconomic factors, healthcare access, or customs [6, 8, 9, 25]. However, they could reflect greater occult metastases in regional lymph
nodes [8, 9]. Molecular approaches, which can quantify small nests of metastatic tumor cells, represent a
technological opportunity to reduce racial disparities
in colorectal cancer mortality [5, 11, 26-29].

Enabling technologies
Histopathology underestimates regional lymph
node metastases, reflecting limitations in tissue volumes sampled and detection sensitivity (one tumor
cell in 200 normal cells) [16]. The significance of these
restrictions can be understood by considering clinically-impactful categories of lymph node metastases,
including those that are greater than 0.2 cm (significant), micrometastases between 0.02 to 0.2 cm (indeterminate significance), and isolated tumor cells less
than 0.02 cm (low significance) [1, 3]. In that context,
evolving molecular approaches provide highly sensitive techniques that detect and characterize small
quantities of cancer cells at metastatic foci. Enabling
technologies, including RT-qPCR, may offer the most
sensitive and specific detection of metastases [4, 5].

GUCY2C, selectively expressed by intestinal epithelial cells, is the receptor for the paracrine factors
guanylin and uroguanylin, whose binding to the extracellular domain activates the catalytic domain in
the cytoplasm, producing cGMP accumulation [11, 30,
31]. GUCY2C regulates epithelial homeostasis, coordinating the cell cycle, chromosomal stability, metabolism, and microenvironmental interactions organizing the crypt-surface axis along the colon and rectum
[32]. Guanylin and uroguanylin are gene products
universally lost early in in colorectal tumorigensis in
animals and humans. GUCY2C silencing in mice increases tumorigenesis, reflecting dysregulation of cell
proliferation and accumulation of DNA damage.
Thus, GUCY2C is a tumor suppressor coordinating
epithelial homeostasis whose silencing through hormone loss contributes to tumorigenesis [32].
The unique expression pattern of GUCY2C, restricted to intestinal epithelial cells normally, suggested that this receptor might be a biomarker for
colorectal cancer. Indeed, GUCY2C was expressed by
>1,000 specimens of normal intestine, but not by
>1,000 extra-gastrointestinal tissues [11, 30, 31]. Also,
GUCY2C mRNA (n>900) and protein (n>200) were
detected in almost all primary and metastatic human
colorectal tumors, but not in extra-gastrointestinal
tumors (>200). Moreover, GUCY2C mRNA and protein are over-expressed by nearly all colorectal tumors. Taken together, these observations underscore
the utility of GUCY2C as a marker for staging patients
with colorectal cancer.

Clinical utility of GUCY2C RT-qPCR for
staging
The utility of GUCY2C RT-PCR as a categorical
variable (yes/no) for detecting occult tumor cells in
regional lymph nodes that predict outcomes [27, 33]
was defined in a prospective multicenter blinded

http://www.jcancer.org
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clinical trial. This trial was supported by an analytically validated sensitive, robust, and reproducible
quantitative RT-PCR (RT-qPCR) method for GUCY2C
[34, 35]. Further, it required unique statistical paradigms for accurate quantification of GUCY2C concentrations that could stratify the prognostic risk of
cohorts of patients providing different numbers of
regional lymph nodes for analysis [11, 36]. In this trial,
257 patients with lymph node-negative (stage I and II)
colorectal cancer were prospectively enrolled at 9
hospitals, providing 2,570 lymph nodes for analysis
by histopathology and RT-qPCR. Patients were
tracked for a median of 24 months and main outcomes
were time to recurrence and disease-free survival [11].
Thirty-two (12.5%) patients had nodes that were negative for GUCY2C, and thirty remained free of disease
(recurrence rate 6.3% [95% CI 0.8-20.8%]). Conversely,
225 (87.5%) patients had regional lymph nodes that
were positive for GUCY2C, and 47 (20.9%
[15.8-26.8%]) developed recurrent disease (P=0.006).
Indeed, GUCY2C in regional lymph nodes was the
most powerful independent marker of prognosis, and
patients who were GUYC2C-positive had earlier time
to recurrence (adjusted hazard ratio 4.66 [1.11-19.57];
P=0.035) and lower disease-free survival (adjusted
hazard ratio 3.27 [1.15-9.29]; P=0.026). Of significance,
this is one of the first prospective multicenter blinded
clinical trial offering level I evidence associating molecular lymph node metastases detected by RT-PCR
with disease recurrence [11]. This trial reveals the
utility of GUCY2C RT-qPCR to detect occult metastatic tumor cells that define disease outcomes. This
approach is quite robust with independent validation
by other laboratories, operators and technology platforms [37-39].
Although a high proportion of histologically
node-negative patients harbor molecular metastases
by GUCY2C RT-qPCR, most of these patients will
never recur [1-3]. Understanding this apparent inconsistency depends on the realization that the presence
of regional lymph node metastases does not insure
disease recurrence but, rather, indicates risk of disease
recurrence. This inability to identify clinically significant from insignificant lymph node metastases represents one key gap in the management of patients
with colorectal cancer. Indeed, this uncertainty can be
appreciated by considering that only about 50% of
stage III patients develop recurrent disease although
all have metastases in regional lymph nodes detectable by histopathology [1-3].
Here, the uncertain clinical significance of occult
metastases underscores the limitations of qualitative
RT-PCR generally for categorical identification of occult metastases, which is the absence of quantitative
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information about metastatic burden [5]. The enhanced sensitivity of RT-PCR, with its maximized
tissue sampling and ability to discriminate single
cells, reveals metastases below the limit of prognostic
risk [1, 5, 11, 28], restricting the specificity of this approach. There is an evolving approach that extends
beyond the categorical detection of cancer cells, to
quantify occult metastatic burden (how much) across
the regional lymph node web to define disease risk
and clinical outcomes. This algorithm originates in,
and extends, established histopathological concepts.
First, a quantitative relationship exists between
prognostic risk and the number of nodes containing
metastatic cancer cells by histopathology. For example, stage III patients with more than 4 involved regional lymph nodes exhibit a recurrence rate which is
greater than patients with fewer than 3 involved
lymph nodes [1-3]. Moreover, a quantitative relationship exists between the volume of metastatic tumor cells in each lymph node and prognostic risk. In
that context, metastases greater than 0.2 cm are associated with increased cancer recurrence while the relationship between individual tumor cells or nests less
than 0.02 cm and risk is unclear [1-3]. The development of quantitative RT-PCR (RT-qPCR) offers a remarkable opportunity to quantify occult metastases to
define prognostic risk and predict the benefit of adjuvant chemotherapy. Indeed, quantification of
GUYC2C expression offers a molecular homologue of
morphological analyses of metastatic volumes in regional lymph nodes. Here, quantification by RT-qPCR
enhances 2-dimensional morphology by estimating
the amount of metastases in large volumes of lymph
node materials, rather than thin sections, and across
all lymph nodes to estimate occult metastatic burden
throughout the regional lymph node web.
Thus, we designed analytic approaches to define
the association of occult metastatic burden, quantified
by GUCY2C RT-qPCR, with outcomes in colorectal
cancer patients to examine the quantitative relationship between occult nodal metastases and prognostic
risk [11, 13]. In this paradigm, relationships between
clinical outcomes, including time to recurrence and
disease-free survival, and occult metastatic burden,
were estimated by recursive partitioning [13]. Here,
176 (60%) stage I-II colon cancer patients exhibited
low tumor burden (MolLow), and all but 4 remained
free of disease (recurrence rate 2.3% [95%CI
0.1-4.5%]). Further, 90 (31%) colon cancer patients
exhibited intermediate tumor burden (MolInt) and 30
(33.3% [23.7%-44.1%]) developed disease recurrence.
Moreover, 25 (9%) colon cancer patients had high
tumor burden (MolHigh), and 17 (68.0%
[46.5%-85.1%]) developed recurrent disease (P<0.001).
http://www.jcancer.org
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Occult tumor burden was an independent marker of
prognosis and patients with MolInt and MolHigh
disease exhibited a graded risk of earlier time to recurrence (MolInt, adjusted hazard ratio 25.52
[11.08-143.18]; P<0.001; MolHigh, 65.38 [39.01-676.94];
P<0.001) and lower disease-free survival (MolInt, 9.77
[6.26-87.26]; p<0.001; MolHigh, 22.97 [21.59-316.16];
P<0.001). This paradigm offers a remarkable enhancement to the use of GUCY2C as a categorical
marker, where 88% of colorectal cancer patients were
GUCY2C-positive with a recurrence risk of 20% [11].
They underscore the clinical opportunity offered by
occult metastatic burden analysis to assign prognostic
risk to patients with lymph node-negative colorectal
cancer. In that context, identifying patients with a
mortality risk equal to patients with disseminated
metastases underscores the prognostic value of occult
metastatic burden analysis. Additionally, patients
with the greatest occult metastatic burden might benefit most from receiving adjuvant chemotherapy.

Racial disparities reflect differences in
occult metastatic burden
Prospective analysis of GUCY2C to detect occult
metastases in regional lymph nodes [11, 13] provided
an opportunity to define the contribution of occult
metastatic burden to racial disparities in outcomes in
colon cancer [12]. Indeed, there was 4-fold greater
levels of occult metastases in individual nodes in 23
African American, compared to 259 Caucasian, patients with colon cancer (p<0.001; 95% CI=3.3, 6.7).
Occult metastatic burden across the regional lymph
node web stratified the whole population into categories with low (60%; recurrence rate (RR)=2.3% [95%
CI 0.1-4.5%]), intermediate (31%; RR=33.3%
[23.7%-44.1%]),
and
high
(9%;
RR=68.0%
[46.5%-85.1%], P<0.001) risk. However, race (P=0.02),
T stage (p=0.02), and number of lymph nodes collected for histology (P=0.003) were independent
prognostic markers of risk. African American patients, compared to Caucasian patients, were most
likely to have levels of occult metastatic burden producing the greatest risk (adjusted odds ratio=5.08
[1.55, 16.65]; P=0.007). These observations underscore
occult metastatic burden as one determinant contributing to racial disparities in stage-specific outcomes in
colorectal cancer. As a correlate, they suggest that
occult metastatic burden may represent a detect-treat
algorithm to reduce racial disparities in mortality in
colorectal cancer.

Number of lymph nodes optimizes the
accuracy of occult metastatic analysis
Not surprisingly, the accuracy of estimating oc-
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cult metastatic burden is dependent on the number of
regional lymph nodes analyzed by RT-qPCR [14].
Indeed, patients providing fewer than 5 regional
lymph nodes exhibited occult metastatic burdens that
identified more than 95% of stage I and II patients as
low and intermediate risk, with few patients in the
highest risk category. Conversely, analysis of more
than 12 regional lymph nodes optimally resolved the
lowest risk cohort, representing 68% of stage I and II
patients. Further, analysis of more than 23 regional
lymph nodes entirely eliminated the intermediate risk
cohort, maximizing the identification of patients with
the greatest recurrence risk, representing approximately 28% of stage I and II patients. Thus, the prognostic utility of occult metastatic burden is related to
the number of regional lymph nodes analyzed by
RT-qPCR. Indeed, these data suggest that the intermediate risk category reflects inaccuracies in estimating occult tumor burden due to insufficient nodal
collections. Based on these data, analysis of more than
12 nodes offers estimates of occult metastatic burden
that maximally define clinical outcomes, resolving
stage I and II cohorts into patients with (1) with a
near-zero likelihood of recurrence (~70%) and (2) a
maximum likelihood (>70%) of recurrence (30%) [14].
Indeed, it may be the case that this algorithm provides
near-perfect prognostic risk stratification, since ~70%
of node-negative patients are cured by surgery, while
~30% develop disease recurrence [1-3].

Future perspectives
Staging patients with colorectal cancer involves
histopathological analyses of tumors and regional
lymph nodes. However, this paradigm under-estimates the presence of metastases, and about
30% of node-negative patients progress to developing
disease recurrence. Limitations in established histopathology techniques, including tissue sampling and
sensitivity, can be overcome using emerging molecular approaches. Indeed, identification of occult metastases in regional lymph nodes is the most powerful
independent indicator of prognostic risk in colorectal
cancer patients. Prospective clinical assessment indicates that analyses of lymph nodes using RT-qPCR
estimates metastatic burden that identifies those stage
I and II patients that will develop recurrent disease.
Further, these approaches suggest that occult metastatic burden is one contributor to racial disparities in
outcomes in African American, compared to Caucasian, patients with colorectal cancer. Moreover, these
at-risk stage I and II patients, black and white, may
remarkably benefit from adjuvant chemotherapy.
Beyond lymph node analysis, genomic paradigms are evolving to extract clinically-important
http://www.jcancer.org
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information from tumors to enhance staging algorithms to improve outcomes. Mutations in oncogenes
or tumor suppressors, transcriptomic analyses, proteomic and metabolomic signatures, and epigenetic
profiling in tumors can personalize evaluations of
risk, identify patients who could benefit from treatment, and predict which treatments will be clinically
active [40-44]. However, the clinical value of molecular analyses of primary tumors is only relevant in the
context of whether primary tumors have metastasized. Indeed, tumors with molecular signature suggesting a poor prognosis represent a risk only if they
are not excised before metastasizing. In that context,
molecular approaches profiling tumors might be of
greatest utility when applied to patients with occult
metastatic burden, rather than to those free of metastases in regional lymph nodes. Here, molecular analyses of lymph nodes provides an opportunity to prioritize expensive tumor analyses to optimize
cost-effective healthcare [11]. Future clinical studies
will explore the utility of analytical algorithms where
patients who are node-negative by histopathology are
reflexed to molecular staging, to quantify occult metastatic burden, followed subsequently by molecular
tumor profiling for patients at increased prognostic
risk, to define treatments individualized to their tumor biology [45].
As a last note, while the technology for RT-qPCR
is evolving, it remains primarily the province of specialty laboratories, with only modest penetration into
hospitals and medical centers. However, molecular
diagnostics is growing business, in excess of $14 billion with projected growth of 10% annually [46, 47]. In
that context, molecular diagnostics approved by the
FDA expanded from 72 in 2006 to 134 in 2009 [48].
Further, molecular tests developed in specialty laboratories were in excess of 1,400 in 2009 [49]. These data
suggest that molecular diagnostics will be increasingly integrated into the clinical care of patients.
While specialty laboratories provide the experience
and validated analytic algorithms consistent with
FDA guidelines and CMS reimbursement in the short
term, these enabling platforms will support integration of molecular staging into disease management
algorithms across the entire healthcare enterprise in
the long term.
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